23:50 , Dec 7, 2018 |  BC Extra  |  Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

Following a spate of resignations this summer, MiMedx Group Inc. (NASDAQ:MDXG) announced three executive promotions. SVP of Strategic Initiatives Mark Landy was promoted to EVP and chief strategy officer. VP of Medical Affairs David Mason...
19:34 , Aug 24, 2018 |  BC Extra  |  Politics & Policy

Allergan, Mohawk Tribe request rehearing in sovereign immunity IPR case

Allergan plc (NYSE:AGN) and the Saint Regis Mohawk Tribe filed a petition on Aug. 20 for an en banc rehearing of their patent case in front of the full U.S. Court of Appeals for the...
19:10 , May 4, 2018 |  BC Week In Review  |  Company News

Fresenius to terminate agreement, Akorn files complaint

Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY) said on April 22 that it will terminate its acquisition agreement with Akorn Inc. (NASDAQ:AKRX) because the generics company failed to fulfill several closing conditions. Fresenius also noted...
15:34 , Mar 30, 2018 |  BC Week In Review  |  Company News

CAFC halts IPR proceedings while Mohawk tribe, Allergan appeal

The U.S. Court of Appeals for the Federal Circuit (CAFC) ordered the Patent Trial and Appeal Board to stay its inter partes review of patents covering Restasis cyclosporine from Allergan plc (NYSE:AGN) until CAFC hears...
18:55 , Mar 29, 2018 |  BC Extra  |  Company News

CAFC halts IPR proceedings while Mohawk tribe, Allergan appeal

The U.S. Court of Appeals for the Federal Circuit (CAFC) ordered the Patent Trial and Appeal Board to stay its inter partes review of patents covering Restasis cyclosporine from Allergan plc (NYSE:AGN) until CAFC hears...
17:21 , Mar 2, 2018 |  BC Week In Review  |  Company News

Fresenius investigating Akorn's alleged breaches of FDA data integrity

In its FY17 earnings report, Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY) said it has engaged external experts to conduct an independent investigation into alleged breaches of FDA data integrity requirements relating to product development...
23:38 , Oct 27, 2017 |  BioCentury  |  Politics, Policy & Law

More on sovereign immunity

A federal judge has thrown a bucket of cold water on Allergan plc ’s attempt to shield its patents by transferring them to a Native American tribe. The disdain for the deal expressed by William...
19:02 , Oct 27, 2017 |  BC Week In Review  |  Company News

Allergan, generics contest sovereign immunity

Allergan plc (NYSE:AGN) and generic drug companies challenging patents covering dry-eye drug Restasis cyclosporine exchanged legal briefs about the pharma’s attempt to use tribal sovereign immunity to shield the patents from inter partes review. The...
21:36 , Oct 24, 2017 |  BC Extra  |  Company News

Allergan, generics contest sovereign immunity

Allergan plc (NYSE:AGN) and generic drug companies challenging patents covering dry-eye drug Restasis cyclosporine have exchanged legal briefs about the pharma’s attempt to use tribal sovereign immunity to shield the patents from inter partes review....
15:16 , Oct 20, 2017 |  BC Week In Review  |  Company News

Allergan insists deal with tribe is not a sham

Allergan plc (NYSE:AGN) argued in court that its patent deal with the Saint Regis Mohawk Tribe was not a sham, according to court briefings filed Oct. 13. The company also argued that both it and...